公开(公告)号：US20240189341A1

公开(公告)日：2024-06-13

申请号：US18011194

申请日：2022-06-21

申请人： REMEGEN CO., LTD.

发明人： Xinling ZHANG ,  Wenting LUO ,  Yue WANG ,  Jie ZHOU ,  Qilin YIN ,  Changjiang HUANG ,  MARIE M. ZHU

IPC分类号： A61K31/724 ,  A61K47/68 ,  A61P35/00 ,  C07K16/32

CPC分类号： A61K31/724 ,  A61K47/6877 ,  A61P35/00 ,  C07K16/32 ,  C07K2317/24

摘要： The present disclosure provides a pharmaceutical combination and use thereof. By using an effective amount of methyl-β-cyclodextrin as a preparation component or a combined auxiliary drug, the efficacy of ADC can be significantly improved, so that some of the ADC drugs with safety issues caused by excessive dosage can be developed. Moreover, due to the reduction in the dosage of ADC drugs, the cost of production and the cost of treatment for patients have also been greatly reduced, thereby being beneficial.